Literature DB >> 2804849

Benzodiazepine use and abuse in Canada.

U Busto1, K L Lanctôt, P Isaac, M Adrian.   

Abstract

Benzodiazepines are frequently prescribed, yet the extent of their use in Canada has not been described. Such data would be valuable in assessing patient exposure to benzodiazepines and would provide a context to estimate the risk-benefit ratio of these drugs. Analysis of benzodiazepine sales in 1978-87 in Canada, expressed as the defined daily dose (DDD) per 1000 inhabitants per day, showed that the use of these drugs was stable during the first half of the decade, at 33 DDD/1000 inhabitants per day, then steadily increased from 1983 to 1987, reaching 48 DDD/1000 inhabitants per day in 1987. The total use of slowly eliminated benzodiazepines declined, whereas the overall use of rapidly eliminated benzodiazepines increased linearly. In 1978-83 Canada had the second-lowest total benzodiazepine use among several Western countries. The patterns of use and abuse of rapidly eliminated benzodiazepines in 1978-84 showed a close correlation. Our findings indicate that data on drug use can be monitored and linked to clinical data, providing a mechanism for monitoring the relation between use and related illness.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2804849      PMCID: PMC1451463     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  13 in total

1.  Withdrawal reaction after long-term therapeutic use of benzodiazepines.

Authors:  U Busto; E M Sellers; C A Naranjo; H Cappell; M Sanchez-Craig; K Sykora
Journal:  N Engl J Med       Date:  1986-10-02       Impact factor: 91.245

Review 2.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

3.  A review of women's psychotropic drug use.

Authors:  R Cooperstock
Journal:  Can J Psychiatry       Date:  1979-02       Impact factor: 4.356

4.  Low-dose dependence in chronic benzodiazepine users: a preliminary report on 119 patients.

Authors:  K Rickels; W G Case; E E Schweizer; C Swenson; R B Fridman
Journal:  Psychopharmacol Bull       Date:  1986

5.  Research on psychotropic drug use. A review of findings and methods.

Authors:  R Cooperstock; P Parnell
Journal:  Soc Sci Med       Date:  1982       Impact factor: 4.634

6.  Purchases of hypnotics, sedatives and minor tranquillizers among 2,566 individuals in the county of Jämtland, Sweden. A 6-year follow-up.

Authors:  G Boethius; B Westerholm
Journal:  Acta Psychiatr Scand       Date:  1977-08       Impact factor: 6.392

7.  A cross-national comparison of anti-anxiety/sedative drug use.

Authors:  M B Balter; D I Manheimer; G D Mellinger; E H Uhlenhuth
Journal:  Curr Med Res Opin       Date:  1984       Impact factor: 2.580

Review 8.  Rebound insomnia and rebound anxiety: a review.

Authors:  A Kales; C R Soldatos; E O Bixler; J D Kales
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

9.  Utilization of psychotropic drugs in Saskatchewan: 1977-1980.

Authors:  B Power; W Downey; B R Schnell
Journal:  Can J Psychiatry       Date:  1983-11       Impact factor: 4.356

10.  Utilization of health and mental health services. Three Epidemiologic Catchment Area sites.

Authors:  S Shapiro; E A Skinner; L G Kessler; M Von Korff; P S German; G L Tischler; P J Leaf; L Benham; L Cottler; D A Regier
Journal:  Arch Gen Psychiatry       Date:  1984-10
View more
  13 in total

Review 1.  Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995.

Authors:  Yoko Murphy; Emily Wilson; Elliot M Goldner; Benedikt Fischer
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

Review 2.  Anxiety disorders. Part 2: Pharmacotherapy with benzodiazepines.

Authors:  A Labelle; Y D Lapierre
Journal:  Can Fam Physician       Date:  1993-10       Impact factor: 3.275

3.  Moderating Benzodiazepine Use in the Elderly: Curbing physicians' prescribing practices.

Authors:  P G Huston
Journal:  Can Fam Physician       Date:  1992-10       Impact factor: 3.275

Review 4.  The diagnosis and management of insomnia in clinical practice: a practical evidence-based approach.

Authors:  A M Holbrook; R Crowther; A Lotter; C Cheng; D King
Journal:  CMAJ       Date:  2000-01-25       Impact factor: 8.262

5.  Use of benzodiazepines and related drugs in Manitoba: a population-based study.

Authors:  Silvia Alessi-Severini; James M Bolton; Murray W Enns; Matthew Dahl; David M Collins; Dan Chateau; Jitender Sareen
Journal:  CMAJ Open       Date:  2014-10-01

6.  Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors.

Authors:  Anne M Hausken; Kari Furu; Svetlana Skurtveit; Anders Engeland; Jørgen G Bramness
Journal:  Eur J Clin Pharmacol       Date:  2008-09-23       Impact factor: 2.953

7.  Are we going to increase the use of antidepressants up to that of benzodiazepines?

Authors:  Arcangelo Ciuna; Margherita Andretta; Letizia Corbari; Deborah Levi; Mersia Mirandola; Adriano Sorio; Corrado Barbui
Journal:  Eur J Clin Pharmacol       Date:  2004-09-23       Impact factor: 2.953

8.  A population-wide profile of prescription drug use in Saskatchewan, 1989.

Authors:  K Quinn; M J Baker; B Evans
Journal:  CMAJ       Date:  1992-06-15       Impact factor: 8.262

Review 9.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

10.  Retrospective population cohort study on hip fracture risk associated with zolpidem medication.

Authors:  Fang-Yu Lin; Pei-Chun Chen; Chun Hui Liao; Yow-Wen Hsieh; Fung-Chang Sung
Journal:  Sleep       Date:  2014-04-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.